A Phase I, Open-Label, Multicenter Study To Assess The Safety, Pharmacokinetics, And Preliminary Antitumor Activity Of Azd4635 Both As Monotherapy And In Combination In Patients With Advanced Solid Malignancies: Results From Prostate Cancer Patients (Nct02740985).